

**Supplementary Table 6.** Baseline characteristics of patients in period 2

Characteristic	Conventional BBI	Structured BBI	P value
Number	93	151	
Age, yr	60.2±12.7	61.7±13.9	0.381
Male sex	30 (32.3)	83 (55.0)	0.001
BMI, kg/m <sup>2</sup>	25.1±4.2	24.2±3.8	0.070
Weight, kg	63.4±11.5	63.7±12.3	0.821
CKD-EPI eGFR, mL/min/1.73 m <sup>2</sup>	69.9±28.6	72.3±29.5	0.541
Diabetes duration, yr	13.6±10.1	15.5±11.2	0.189
HbA1c, %	10.6±2.0	10.5±2.2	0.630
Concurrent antidiabetic medications	0.85±0.72	1.10±0.74	0.011
Biguanide			
Metformin	50 (53.8)	94 (62.3)	0.240
Insulin secretagogues			
Sulfonylurea	20 (21.5)	46 (30.5)	0.167
Glinide	10 (10.8)	5 (3.3)	0.038
Others			
DPP4i	4 (4.3)	42 (27.8)	<0.001
Thiazolidinedione	4 (4.3)	6 (4.0)	0.999
SGLT2i	0	5 (3.3)	0.191
α-Glucosidase inhibitor	3 (3.2)	2 (1.3)	0.580
GLP-1 RA	2 (2.2)	1 (0.7)	0.670

Values are presented as mean ± standard error or number (%). Age, sex, BMI, weight, eGFR, diabetes duration, and HbA1c level were 1:1 matched using the nearest neighbor method with a caliper width of 0.2.

BBI, basal-bolus insulin; BMI, body mass index; CKD-EPI eGFR, Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate; HbA1c, glycated hemoglobin; DPP4i, dipeptidyl peptidase 4 inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist.